11/06/2024
6:31 AM | Arbutus Biopharma (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
10/15/2024
7:26 AM | Arbutus Biopharma (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
10/11/2024
3:07 PM | Arbutus Biopharma (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
08/01/2024
6:31 AM | Arbutus Biopharma (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
06/10/2024
3:50 PM | Arbutus Biopharma (Subject)
MORGAN STANLEY (Filed by)
| Form SC 13G | |
06/06/2024
10:16 AM | Arbutus Biopharma (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
06/05/2024
5:00 AM | Arbutus Biopharma (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
|
05/28/2024
3:25 PM | Arbutus Biopharma (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
05/24/2024
3:07 PM | Arbutus Biopharma (Issuer)
Torti Frank (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
05/22/2024
5:00 AM | Arbutus Biopharma (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
05/17/2024
8:03 AM | Arbutus Biopharma (Subject)
Whitefort Capital Management, LP (Filed by)
| Form SC 13D/A | |
05/09/2024
7:00 AM | Arbutus Biopharma (Subject)
Whitefort Capital Management, LP (Filed by)
| Form SC 13D | |
05/02/2024
3:32 PM | Arbutus Biopharma (Filer)
| Form 10-Q
General form for quarterly reports under Section 13 or 15(d) | |
05/02/2024
6:31 AM | Arbutus Biopharma (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
05/02/2024
6:26 AM | Arbutus Biopharma (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
04/10/2024
3:05 PM | Arbutus Biopharma (Filer)
| Form DEF 14A | |
04/10/2024
3:06 PM | Arbutus Biopharma (Filer)
| Form DEFA14A | |
04/04/2024
7:31 AM | Arbutus Biopharma (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
02/29/2024
6:31 AM | Arbutus Biopharma (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
02/12/2024
8:41 AM | Arbutus Biopharma (Subject)
BlackRock Inc. (Filed by)
| Form SC 13G/A | |
02/05/2024
6:54 PM | Arbutus Biopharma (Issuer)
McElhaugh Michael J. (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
02/05/2024
6:54 PM | Arbutus Biopharma (Issuer)
Sofia Michael J. (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
02/05/2024
6:54 PM | Arbutus Biopharma (Issuer)
HASTINGS DAVID C (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
02/05/2024
6:55 PM | Arbutus Biopharma (Issuer)
Sims Karen (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
02/05/2024
6:55 PM | Arbutus Biopharma (Issuer)
Naftzger J. Christopher (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
01/08/2024
6:31 AM | Arbutus Biopharma (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
01/04/2024
3:09 PM | Arbutus Biopharma (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
11/21/2023
7:00 AM | Arbutus Biopharma (Subject)
Two Seas Capital LP (Filed by)
| Form SC 13G | |
Free ABUS Stock Alerts